Floatz logo

Monomethyl Fumarate

Lymphoid Malignancies

Case Comprehensive Cancer CenterSmall moleculeEarly Phase 1Dormant
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
95/ 100

Competitive context

6 Active assets in the Lymphoid Malignancies cohort.

Asset / SponsorPhaseRating
Cyclophosphamide
Case Comprehensive Cancer Center
Phase 2BB
Abt-263
AbbVie
Phase 1/2B
Pralatrexate
Jennifer Amengual
Phase 1/2CCC
Venetoclax
National Cancer Institute (NCI)
Phase 1/2CCC
Romidepsin
Columbia University
Phase 1/2CCC

View all 21 →

Same molecule, other indications

Monomethyl Fumarate is also rated in:

Blood Stem Cell Transplant FailureDormant
BBB
Indicative ·
76 / 100
View asset →
Fanconi AnemiaDormant
BBB
Indicative ·
74 / 100
View asset →
Refractory Anemia With Excess BlastsDormant
BBB
Indicative ·
73 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →